Nascent Biotech granted Japanese patent for crossing blood-brain barrier

Nascent Biotech announced the Company has been issued a “Method-of-Use” patent from the Japanese Patent Office for its primary asset, Pritumumab. Specifically, the patent approval is related to PTB’s capacity to cross through the Blood-Brain Barrier. The patent allowance recognizes PTB’s ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB. In basic terms, the blood-brain barrier is a semipermeable border of endothelial cells that act as a filtering mechanism for the capillaries that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances from the circulatory system into the brain.